As part of its strategy for preventing bacterial illnesses similar to those found in Abbott Laboratories’ products, the U.S. regulator for health said Tuesday that it will review guidelines and rules regarding infant formula manufacturing.
It said that the Food and Drug Administration will consider whether to create a dedicated team of investigators and realign employees across two divisions in order to support regulatory oversight of infant formulations.
Following complaints about infection by cronobacter, the FDA issued this statement.
The shutdown of the plant and the recalls of Abbott infant formula products exacerbated a shortage, sending parents in the United States scrambling. In July, Abbott’s plant was reopened.
Although the infection is rare in most states and not reported in many, it can cause serious complications in newborns. Following reports of four cases, and two deaths, Abbott products were recalled.